NeurAxis (NRXS): Growth-Stage Medtech

In this Business Breakdown, David Barbato and Sergio Heiber sit down with NeurAxis’s (NRXS) CEO Brian Carrico. The company was originally profiled by Sergio Heiber on August 18, 2024, at $3.14 USD per share. This discussion took place live on February 18th, 2026, on the MicroCapClub Community. Not part of the community? Join us.

In this conversation, Brian Carrico, CEO of Neuroaxis, discusses the company's growth, the significance of the Category One CPT code, and the current market position. He highlights the importance of strong data for insurance coverage and reimbursement, the focus on pediatric healthcare, and the expansion into the VA market. The discussion also covers the company's treatment mechanisms, ongoing clinical trials, and strategies for scaling operations. Audience questions provide further insights into insurance negotiations and market opportunities.

You can listen/watch this business breakdowns on Spotify, Apple PodcastD, and YouTube below:

_{Disclaimer: All content in this newsletter is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this newsletter and MicroCapClub.com. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and MicroCapClub.com are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed on MicroCapClub.com is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of publication and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information. FULL DISCLAIMER and TERMS OF USE}